Roger Hill, MD
Interventional Cardiology · Jonesboro, ARNPI 1043215023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.
Across 438 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abiomed$1K
- Abbott$1K
- Medtronic$1K
- Amgen$547
- Shockwave Medical, Inc$544
- plus $3K from 24 others
Across 4 payments — averaging $4059.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
- Amgen$82
What the payments were for
- Food & beverage$9,713100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 92 | $1,871 |
| Abiomed | 24 | $1,488 |
| Abbott | 48 | $1,194 |
| Medtronic(2 entities) | 72 | $1,019 |
| Amgen | 27 | $547 |
| Shockwave Medical, Inc | 18 | $544 |
| Novartis | 29 | $445 |
| Pfizer | 27 | $390 |
| Cvrx, Inc. | 7 | $316 |
| Johnson & Johnson | 17 | $297 |
| AstraZeneca | 8 | $180 |
| Avinger Inc. | 9 | $180 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $168 |
| Livanova USA, Inc. | 2 | $152 |
| Atricure, Inc. | 2 | $137 |
| Sanofi-aventis U.S. LLC | 3 | $117 |
| Boehringer Ingelheim | 8 | $112 |
| Irhythm Technologies, Inc. | 8 | $104 |
| Daxor Corporation | 1 | $93 |
| Cordis US CORP. | 3 | $52 |
| Edwards Lifesciences | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Merck | 4 | $49 |
| Bard Peripheral Vascular, Inc. | 2 | $40 |
| Haemonetics Corporation | 1 | $39 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Biotronik Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$344
- LifeSPARC$132
- GENERAL VASCULAR INTERVENTION$128
- Ultreon$128
- Barostim Neo System$119
- GENERAL - STENTS$101
How this compares
$9,721 in reported general payments places this provider in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 118 | $181,764 |
| EliquisApixaban | 240 | $158,927 |
| EntrestoSacubitril/Valsartan | 81 | $66,935 |
| Praluent PenAlirocumab | 38 | $51,344 |
| XareltoRivaroxaban | 41 | $40,430 |
| BrilintaTicagrelor | 22 | $14,790 |
| JardianceEmpagliflozin | 14 | $10,785 |
| Ezetimibe | 430 | $8,242 |
| FarxigaDapagliflozin Propanediol | 11 | $7,289 |
| VascepaIcosapent Ethyl | 11 | $5,143 |
| Atorvastatin Calcium | 579 | $4,863 |
| Ranolazine ErRanolazine | 69 | $3,950 |
| ClopidogrelClopidogrel Bisulfate | 379 | $3,339 |
| Midodrine Hcl | 48 | $2,192 |
| Carvedilol | 393 | $1,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $390 | $158,927240 claims |
| NovartisEntresto | $445 | $66,93581 claims |
| Johnson & JohnsonXarelto | $297 | $40,43041 claims |
| AstraZenecaBrilinta, Farxiga | $180 | $22,07933 claims |
| Boehringer IngelheimJardiance | $112 | $10,78514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Jonesboro
- Lena AwarJonesboro$43K
- Amer HawatmehJonesboro$20K
- Ahmed AhmedJonesboro$19K
- John McKeeJonesboro$7K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Zubair AhmedFayetteville$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.